| Metric | Q2'26 | Q3'26 | Change |
|---|---|---|---|
| Reported Revenue | $11.99B, +10% YoY | $12.14B, +9% YoY | YoY reported growth slowed by 1 percentage point. |
| Organic Revenue Growth | 5% in Q2 (prior call operating review) | 6% | YoY organic growth increased by 1 percentage point. |
| Adjusted EPS | $6.03, +13% YoY | $6.68, +15% YoY | Accelerating growth, but 15c was one-time tariff refund |
| Adjusted Operating Income | $2.73B, +15% YoY | $2.97B, +15% YoY | Same growth rate on larger base |
| Adjusted Operating Margin | 22.8%, +90bps | 24.5%, +120bps | Q3 YoY expansion includes 50 basis points from net tariff refunds. |
| Life Sciences Solutions Organic Growth | 3% | 1% | YoY organic growth slowed by 2 percentage points. |
| Analytical Instruments Organic Growth | 7% | 6% | YoY organic growth slowed by 1 percentage point. |
| Specialty Diagnostics Organic Growth | 5% | Flat | Growth stalled |
| Lab Products & Biopharma Services Organic Growth | 5% | 10% | Growth accelerated; pharma-services customer timing favored Q3. |
| YTD Cash Flow from Operations | $3.3B | $5.9B | Cumulative periods differ: six months versus nine months. Not a cash-conversion comparison. |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.